Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 13
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 14
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 15
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 16
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 17
Bristol-Myers Squibb Enters into Research Agreement with NCCN 18
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 19
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute Form Joint Venture 20
Juno Therapeutics Enters into Research Agreement with FHCRC 21
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 22
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 23
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 24
Licensing Agreements 26
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 26
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 27
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 28
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Juno Therapeutics Enters into Licensing Agreement with FHCRC 31
National Comprehensive Cancer Network – Key Competitors 32
National Comprehensive Cancer Network – Key Employees 33
National Comprehensive Cancer Network – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Government and Public Interest 36
Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 36
Sep 27, 2017: Study Finds “Standard Care” Treatments in Breast Cancer Clinical Trials Not Always Standard 37
May 19, 2017: NCCN and Pfizer Address Quality Improvement in Breast Cancer through Clinical Pathways 38
Sep 26, 2016: NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms 39
Aug 29, 2016: New NCCN Imaging Appropriate Use Criteria Published for Eight Cancer Types 40
Apr 11, 2016: Helsinn Supports the Development of NCCN Guidelines For Patients on Nausea and Vomiting, with a Sponsorship Grant 41
Mar 21, 2016: Interventions Required to Reduce Non-Cancer-Related Hospitalizations for Elderly Men after Prostate Cancer Diagnosis, Study Finds 42
Feb 22, 2016: NCCN, in Collaboration With Pfizer, Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives 43
Feb 12, 2016: New NCCN Guidelines Include Evidence Blocks to Illustrate Value in Breast, Colon, Kidney, and Rectal Cancers 44
Product News 45
Jan 27, 2016: Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care With Big Data 45
Other Significant Developments 46
Oct 04, 2016: New NCCN Patient Resources Assist Decision-Making for People With Stomach Cancer 46
Mar 03, 2016: NCCN Publishes New Patient Education Resources for Patients with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma—a Rare, Yet Curable, Blood Cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Key Facts 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Comprehensive Cancer Network, Deals By Therapy Area, 2011 to YTD 2017 9
National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 13
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 14
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 15
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 16
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 17
Bristol-Myers Squibb Enters into Research Agreement with NCCN 18
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 19
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 20
Juno Therapeutics Enters into Research Agreement with FHCRC 21
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 22
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 23
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 24
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 26
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 27
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 28
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Juno Therapeutics Enters into Licensing Agreement with FHCRC 31
National Comprehensive Cancer Network, Key Competitors 32
National Comprehensive Cancer Network, Key Employees 33
National Comprehensive Cancer Network, Subsidiaries 35
【免責事項】
http://www.globalresearch.jp/disclaimer